Welcome to our dedicated page for Golden Sun Technology Group Ltd. SEC filings (Ticker: GSUN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Golden Sun Technology Group Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Golden Sun Technology Group Ltd.'s regulatory disclosures and financial reporting.
Golden Sun Technology Group Ltd. director Hao Yidong filed an initial ownership report on Form 3. This filing establishes his status as a director and provides a baseline disclosure of his equity position in the company, without reporting any recent share purchases, sales, or other transactions.
Golden Sun Technology Group Limited, a Cayman holding company with operations in China, reports a major shift from education into e-commerce marketing services. More than 90% of revenue now comes from data‑driven promotion and advertising support on Chinese short‑video platforms, while tutorial services are maintained only on a limited basis.
For the fiscal year ended September 30, 2025, revenue from continuing operations rose to approximately $35.5 million, up about $29.4 million or 483%, mainly from e‑commerce expansion. Despite this growth, the company recorded a net loss of about $5.2 million, 32% higher than the prior year, and its auditor expressed substantial doubt about its ability to continue as a going concern.
As of September 30, 2025, Golden Sun reported an accumulated deficit of $23.6 million, cash of roughly $0.8 million, current assets of about $12.7 million and current liabilities of about $10.6 million. The company implemented a one‑for‑ten share consolidation and, as of that date, had 8,325,870 Class A and 403,000 Class B ordinary shares outstanding. It also changed its name to reflect its new technology and e‑commerce strategy, while highlighting extensive regulatory, licensing, data‑security, tax and PRC policy risks, including exposure to evolving rules on private education, e‑commerce compliance and U.S. oversight under the HFCA Act.
Golden Sun Technology Group Limited has changed its corporate name from “Golden Sun Health Technology Group Limited” to “Golden Sun Technology Group Limited.” The company expects its Class A ordinary shares to begin trading on the Nasdaq Capital Market under the new name on February 5, 2026, while its CUSIP number will stay the same.
The company explains that the new name reflects its updated business strategy and future development plans, including its shift since November 2023 from a primary focus on tutorial services toward data analytics–driven e-commerce marketing and social media promotion services for small and medium-sized businesses in China.
The filing presents the matters submitted for shareholder approval at Golden Sun Technology Group Limited's upcoming meeting. Shareholders are asked to re-elect seven directors and ratify the re-appointment of AssentSure PAC as the company’s independent registered public accounting firm. Two related special resolutions seek to change the company’s English and dual foreign names to remove the word "Health" and to adopt amended constitutional documents to reflect that name change. Another special resolution would implement a Class B variation subject to Class A and B consent. The company also proposes a sizable increase in authorized share capital from US$50,000 to US$1,000,000 and related amendments to the memorandum, plus an ordinary resolution to allow adjournment of the AGM if further proxy solicitation is needed.
Golden Sun Health Technology Group Limited reported a change in its chief operating officer role. On September 18, 2025, Ms. Xiaoyi Wang resigned as COO for personal reasons, and the company stated her departure did not involve any dispute with management or the board. The board appointed Mr. Duo Ye as the new COO, effective the same day.
Mr. Ye brings more than a decade of senior management experience across financial services, asset management, cultural media, and cross-border e-commerce. On September 24, 2025, the company entered into a three-year employment agreement with him, running from September 18, 2025 to September 17, 2028, with automatic renewal unless either party gives two months’ notice. He will receive a monthly salary of $3,233 plus standard benefits, and the agreement allows termination for cause and includes customary confidentiality and non-disclosure covenants. The company states there are no family relationships or related-party transactions involving Mr. Ye.
Golden Sun Health Technology Group Limited reported that on August 27, 2025 it received formal notice from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market. The company now meets all applicable criteria for continued listing, although Nasdaq will continue to monitor its status and could initiate a new delisting process if future periodic financial statements show that it no longer satisfies the minimum stockholders’ equity rule.
Golden Sun Health Technology Group Limited reports that its two accredited investors have fully exercised their warrant and converted all principal and interest under a prior convertible note into equity. On August 22, 2025, this transaction resulted in the issuance of 6,747,926 Class A ordinary shares to the investors. The original note had an aggregate principal amount of $5,000,000.
The company states that the carrying value of the note and warrant, about $9.4 million as of March 31, 2025, will be reclassified to total equity as of August 25, 2025. Because this increases shareholders’ equity, the company believes it now meets Nasdaq’s minimum $2.5 million shareholder equity requirement for continued listing and is waiting for a formal compliance determination from Nasdaq staff.
Form 144 notice by an insider of Golden Sun Health Technology Group Limited (GSUN) reporting a proposed sale of Class A ordinary shares. The filing lists a proposed sale of 140,108 Class A ordinary shares through WestBull Securities Limited (Hong Kong) on the Nasdaq with an aggregate market value of $378,291.60 and 1,577,944 shares outstanding reported. The table discloses prior acquisitions of Class A shares: 14,460 shares purchased 04/02/2020, 57,840 shares purchased 10/19/2020, and 4,820 shares purchased 10/19/2020, with payment in USD. The filer attests they possess no undisclosed material adverse information and includes the standard Rule 144 and signature attestations.
Golden Sun Health Technology Group Limited is notifying investors about upcoming shareholder meetings and related proxy materials. The company will hold an extraordinary general meeting for holders of Class A ordinary shares on September 25, 2025, followed by its 2025 annual general meeting of shareholders on the same date.
The company is distributing a combined notice and proxy statement for Class A shareholders and a separate notice and proxy statement for Class B shareholders, both dated August 15, 2025. It is also providing proxy cards for Class A and Class B holders so they can vote on the matters to be presented at these meetings.
Golden Sun Health Technology Group Limited filed an amended Form 6-K to add details about an amendment to its existing financing. The company had previously issued a Senior Secured Convertible Note with an aggregate principal amount of $5,000,000 to two accredited investors under a Securities Purchase Agreement dated October 28, 2024, with closing on December 3, 2024. On August 15, 2025, the company and these investors signed Amendment No. 1 to the note, which removes the Adjusted Floor Price defined in the original note and any related adjustments. The amendment is attached as Exhibit 4.1 and this amended Form 6-K is also incorporated by reference into the company’s effective Form F-1 registration statement and related prospectuses.